DATE – Talk Bio

Kane Biotech Announces Third Quarter 2025 Financial Results

6 days ago talkbio0Tagged Clearance, distributor network, financial results, gross profit, Kane Biotech, net loss, Revenue, revyve, third quarter 2025, United States, United States Food and Drug Administration, wound care

Kane Biotech; third quarter 2025; financial results; revenue; gross profit; net loss; revyve; wound care; FDA 510(k) clearance; U.S. distributor network

Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Data in Leptomeningeal Metastases at SABCS 2025

6 days ago talkbio0Tagged central nervous system cancers, Dosage, Escalation, Metastatic Malignant Neoplasm to the Leptomeninges, Phase 1 (qualifier value), Plus Therapeutics, poster spotlight, ReSPECT-LM, REYOBIQ, SABCS, San Antonio Breast Cancer Symposium, Therapeutic radiology procedure

Plus Therapeutics; ReSPECT-LM; Phase 1; dose escalation; REYOBIQ; leptomeningeal metastases; San Antonio Breast Cancer Symposium; SABCS 2025; poster spotlight; central nervous system cancers; radiotherapeutics

Cereno Scientific Secures SEK 100m in Directed Share Issue and SEK 350m Loan Financing, Targeting Milestones by Q4 2027

1 week ago talkbio0Tagged Cardiovascular Diseases, Cereno Scientific, Clinical Development, Directed share, Histone deacetylase inhibitor, Infrequent, Loan, loan financing, milestones, portfolio, Problem, Pulmonary arterial hypertension

Cereno Scientific; SEK 100 million; Directed share issue; SEK 350 million; Loan financing; Q4 2027 milestones; HDAC inhibitor portfolio; Pulmonary arterial hypertension; Clinical development; Rare cardiovascular diseases

Recent Developments in Medical Affairs Reputation and Hemophilia A Management in the US (2025)

1 week ago talkbio0Tagged Acquired (qualifier value), Centers for Disease Control and Prevention (U.S.), federal funding, gene therapy, Health Policy, Hemophilia A, Hemophilia A Pipeline, Hemophilia Treatment Centers, HRSA, Medical Affairs, Programs - Publication Format, public health policy, reputation, U.S.

Medical Affairs; Reputation; Hemophilia A; US; 2025; Gene Therapy; Public Health Policies; Hemophilia Treatment Centers; 340B Program; Federal Funding; Acquired Hemophilia A Pipeline; Healthcare Policy; CDC; HRSA

Gan & Lee Pharmaceuticals Initiates Phase 3 Clinical Study (GRADUAL-3) of the First Chinese Once-Monthly GLP-1 RA for Weight Management

2 weeks ago talkbio0Tagged Chinese Language, Clinical Research, Gan & Lee Pharmaceuticals, Glucagon-Like Peptide 1, GRADUAL-3, innovation, once-monthly, Phase 3, Rheumatoid Arthritis, Weight maintenance regimen

Gan & Lee Pharmaceuticals; Phase 3 clinical study; GRADUAL-3; once-monthly GLP-1 RA; weight management; Chinese innovation

BridgeBio Oncology Therapeutics: Recent News Overview (November 2025)

2 weeks ago talkbio0Tagged AACR-NCI-EORTC, BridgeBio Oncology Therapeutics, clinical-stage biopharma, de-SPAC transaction, financial results, financing characteristics, Helix Acquisition Corp II, PI3Kδ, Piperine Extract (Standardized), ras Oncogene, third quarter 2025

BridgeBio Oncology Therapeutics; Helix Acquisition Corp II; de-SPAC transaction; PIPE financing; RAS and PI3Kα; clinical-stage biopharma; AACR-NCI-EORTC Conference; third quarter 2025 financial results

ASH 2025: Breakthroughs in In Vivo CAR-T Data from Kelonia; Phase 3 Wins for Lilly, J&J, and Novartis

2 weeks ago talkbio0Tagged 2025, Asymmetric Septal Hypertrophy, CAR-T, CAR-T therapy, Eli Lilly, in vivo, Kelonia Therapeutics, Multiple Myeloma, Novartis, Phase 3 trials

ASH 2025; in vivo CAR-T; Kelonia Therapeutics; KLN-1010; multiple myeloma; Johnson & Johnson; Lilly; Novartis; CAR-T therapy; Phase 3 trials

Diamyd Medical’s Pivotal Phase 3 Type 1 Diabetes Trial Clears Final Safety Review Ahead of Early Readout in March 2026

3 weeks ago talkbio0Tagged Accelerated, approval pathway, Data Safety, Diabetes Mellitus, Insulin-Dependent, DIAGNODE-3, Diamyd Medical, DSMB, fast-track designation, Genotype, HLA DR3-DQ2, interim readout, Monitoring Board, orphan drug designation, Phase 3 trial, precision therapy, safety review

Diamyd Medical; Type 1 Diabetes; Phase 3 trial; DIAGNODE-3; safety review; Data Safety Monitoring Board (DSMB); interim readout; March 2026; HLA DR3-DQ2 genotype; Orphan Drug Designation; Fast Track Designation; accelerated approval pathway; precision therapy

Compugen Reports Third Quarter 2025 Results: Earnings Beat, Clinical Progress, and Cash Runway Extended

4 weeks ago talkbio0Tagged AstraZeneca, cash runway, Clinical Trials, clinical-stage immunotherapy, COM503, COM701, Compugen, earnings beat, Gilead, GS-0321, net loss, Revenue, rilvegostomig, third quarter 2025

Compugen; third quarter 2025; earnings beat; clinical-stage immunotherapy; revenue; net loss; cash runway; clinical trials; COM701; COM503 (GS-0321); rilvegostomig; AstraZeneca; Gilead

Spotlight On: What to Watch at AHA 2025 – Key Science and Trends

4 weeks ago talkbio0Tagged 2025, Autoimmune hemolytic anemia, Cardiology discipline, cardiometabolic, Cardiopulmonary Resuscitation, Clinical Trials, coronary trials, gene editing therapies, Guidelines, Hypertensive disease, Interventional procedure, lipid management, Medical Valves, polypill, Science

AHA 2025; late-breaking science; clinical trials; cardiology; gene-editing therapies; polypill; lipid management; valve and coronary trials; cardiometabolic intervention; hypertension; CPR guidelines